.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a mean follow-up of 11 months, individuals along with metastatic intestinal tumors that received biomarker-matched treatments based on circulating growth DNA profiling presented a greater professional perk than those getting unmatched treatment.